Novartis Ag ADR (NVS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2008 | 06-2008 | 03-2008 | 12-2007 | 09-2007 | |
| Cash Flows From Operating Activities | |||||
| Net Income | 6,656,000 | 4,574,000 | 2,308,000 | 6,540,000 | 5,609,000 |
| Depreciation Amortization | 2,119,000 | 1,258,000 | 634,000 | N/A | 2,073,000 |
| Income taxes - deferred | 1,084,000 | 746,000 | 408,000 | N/A | 693,000 |
| Accounts receivable | N/A | N/A | N/A | -204,000 | N/A |
| Accounts payable and accrued liabilities | N/A | N/A | N/A | 323,000 | N/A |
| Other Working Capital | -3,142,000 | -2,708,000 | -1,823,000 | -2,116,000 | -2,938,000 |
| Other Operating Activity | -152,000 | -329,000 | 162,000 | 4,667,000 | 810,000 |
| Operating Cash Flow | $6,565,000 | $3,541,000 | $1,689,000 | $9,210,000 | $6,247,000 |
| Cash Flows From Investing Activities | |||||
| Change In Deposits | -6,470,000 | 5,452,000 | 3,837,000 | -3,331,000 | -2,716,000 |
| PPE Investments | -1,201,000 | -801,000 | -403,000 | -2,415,000 | -1,795,000 |
| Net Acquisitions | -691,000 | N/A | N/A | -52,000 | -52,000 |
| Purchase Of Investment | N/A | N/A | N/A | -295,000 | N/A |
| Sale Of Investment | N/A | N/A | N/A | 352,000 | N/A |
| Purchase Sale Intangibles | -276,000 | -166,000 | N/A | -477,000 | N/A |
| Other Investing Activity | -276,000 | -166,000 | 0 | -503,000 | 0 |
| Investing Cash Flow | $-8,638,000 | $4,485,000 | $3,434,000 | $-6,244,000 | $-4,563,000 |
| Cash Flows From Financing Activities | |||||
| Change In Short Term Borrowing | 5,040,000 | 4,367,000 | -409,000 | -2,111,000 | -666,000 |
| Debt Issued | N/A | N/A | N/A | 11,000 | N/A |
| Debt Repayment | N/A | N/A | N/A | -59,000 | N/A |
| Common Stock Issued | N/A | N/A | N/A | 1,849,000 | N/A |
| Common Stock Repurchased | -483,000 | -512,000 | 142,000 | -6,448,000 | -3,099,000 |
| Dividend Paid | -3,382,000 | -3,365,000 | -3,422,000 | -2,638,000 | -2,397,000 |
| Other Financing Activity | -79,000 | 69,000 | 51,000 | 78,000 | 7,976,000 |
| Financing Cash Flow | $1,096,000 | $559,000 | $-3,638,000 | $-9,318,000 | $1,814,000 |
| Exchange Rate Effect | 66,000 | 124,000 | 86,000 | 298,000 | 97,000 |
| Beginning Cash Position | 5,360,000 | 5,360,000 | 5,360,000 | 3,815,000 | 3,815,000 |
| End Cash Position | 4,449,000 | 14,069,000 | 6,931,000 | 5,360,000 | 7,414,000 |
| Net Cash Flow | $-911,000 | $8,709,000 | $1,571,000 | $1,545,000 | $3,599,000 |
| Free Cash Flow | |||||
| Operating Cash Flow | 6,565,000 | 3,541,000 | 1,689,000 | 9,210,000 | 6,247,000 |
| Capital Expenditure | -1,445,000 | -967,000 | -403,000 | -2,549,000 | -1,795,000 |
| Free Cash Flow | 5,120,000 | 2,574,000 | 1,286,000 | 6,661,000 | 4,452,000 |